| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal NG131: Prostate cancer: diagnosis and management |
|
Medicine details |
|
| Medicine name | histrelin (Vantas®) |
| Formulation | 50 mg implant |
| Reference number | 46 |
| Indication | Palliative treatment of advanced prostate cancer |
| Company | Orion Pharma (UK) Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/04/2009 |
| NICE guidance | |